Table 3.
MTHFR, MTR, MTRR and TS genotype distributions, and odds ratios (OR) for head and neck squamous cell carcinoma
| Polymorphism | No. cases | No. controls | OR1 † (95% CI) | P‐value | OR2 ‡ (95% CI) | P‐value |
|---|---|---|---|---|---|---|
| MTHFR (C677T) | ||||||
| CC | 88 (37.1%) | 252 (35.4%) | 1.00 (reference) | 1.00 (reference) | ||
| CT | 113 (47.7%) | 331 (46.6%) | 0.98 (0.71–1.36) | 0.98 (0.63–1.52) | ||
| TT | 36 (15.2%) | 128 (18.0%) | 0.80 (0.51–1.25) | 0.39 | 0.77 (0.42–1.41) | 0.46 |
| MTHFR (A1298C) | ||||||
| AA | 149 (62.9%) | 453 (63.7%) | 1.00 (reference) | 1.00 (reference) | ||
| AC | 79 (33.3%) | 222 (31.2%) | 1.09 (0.78–1.51) | 1.07 (0.69–1.66) | ||
| CC | 8 (3.4%) | 31 (4.4%) | 0.79 (0.36–1.75) | 0.96 | 0.82 (0.28–2.46) | 0.97 |
| UK § | 1 (0.4%) | 5 (0.7%) | ||||
| MTR (A2756G) | ||||||
| AA | 151 (63.7%) | 496 (69.8%) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 75 (31.6%) | 195 (27.4%) | 1.26 (0.91–1.73) | 1.18 (0.76–1.83) | ||
| GG | 11 (4.6%) | 20 (2.8%) | 1.83 (0.84–3.97) | 0.06 | 1.30 (0.49–3.44) | 0.38 |
| MTRR (A66G) | ||||||
| AA | 108 (45.6%) | 332 (46.7%) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 100 (42.2%) | 315 (44.3%) | 0.97 (0.71–1.33) | 0.85 (0.55–1.31) | ||
| GG | 29 (12.2%) | 64 (9.0%) | 1.39 (0.85–2.26) | 0.38 | 1.25 (0.64–2.44) | 0.89 |
| TS VNTR | ||||||
| Non‐2R/Non‐2R | 168 (70.9%) | 502 (70.6%) | 1.00 (reference) | 1.00 (reference) | ||
| 2R/Non‐2R | 64 (27.0%) | 188 (26.4%) | 1.02 (0.73–1.42) | 1.14 (0.72–1.78) | ||
| 2R/2R | 5 (2.1%) | 21 (3.0%) | 0.71 (0.26–1.91) | 0.78 | 0.66 (0.15–2.90) | 0.84 |
†
OR1 was matched for age and sex.
‡
‡ OR2 was matched for age and sex and adjusted for drinking habit, smoking habit, non‐alcohol energy intake, carotene intake, vitamin C intake, vitamin E intake, folate intake, multivitamin use, dental brushing and referral pattern to our hospital.
§
§ UK denotes genotype unknown. CI, confidence interval.